Compare CVS Health Corp (CVS) vs Nike Inc (NKE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Nike Inc — how do they compare? CVS Health Corp trades at $86.27 (market cap $112.29B), while Nike Inc trades at $34.98 (market cap $51.60B). The key difference: CVS Health Corp is far larger — about 2.2× Nike Inc's market cap, and Nike Inc pays the higher dividend (4.72%). Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Nike Inc for 155 Days on average.
| CVS | NKE | |
|---|---|---|
Market Cap | $112.29B | $51.60B |
Volume | 7,763,676 | 43,506,062 |
Sector | Health | Consumer Cyclical |
52-Week High | $110.60 | $69.68 |
52-Week Low | $70.08 | $33.87 |
Typical Hold Time | 83 Days | 155 Days |
Enterprise Value | $174.64B | $54.30B |
Dividend Yield | 3.03% | 4.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.95, up 1.76% on the day, with a bullish technical signal and strong analyst support. Recent earnings beats in Q1 and Q2 2026, alongside steady revenue growth to $402.07B in 2025, highlight operational strength. The stock's valuation appears attractive with a P/E of 23.17 and P/S of 0.27, while a consensus price target of $111.20 suggests significant upside potential. Positive news includes Aetna's 2027 Medicare plan enhancements and a declared quarterly dividend.
The outlook for CVS remains positive, driven by earnings momentum and strategic initiatives in healthcare services. Key risks include reimbursement pressures and regulatory scrutiny, but Wall Street's 85% buy rating and institutional interest underscore confidence. Investors should weigh the stock's growth prospects against margin volatility and debt levels, with the current price offering a favorable entry point relative to targets.
Nike's stock trades at $34.36, down 0.72% with a bearish technical outlook. The company reported $46.31B in revenue for 2025 with a 6.74% net margin, though earnings have beaten expectations in recent quarters. Analyst consensus remains positive with a $36.98 price target, while recent news highlights challenges in China and inventory management.
Nike faces near-term headwinds from slowing revenue growth and margin pressure, but strong brand positioning and consistent earnings beats provide upside potential. Key risks include consumer demand weakness and competitive pressures, while institutional sentiment remains cautiously optimistic for a turnaround.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Nike Inc
NIKE, Inc. designs, develops, and markets athletic footwear, apparel, equipment, and accessory products for men, women, and children. The Company sells its products worldwide to retail stores, through its own stores, subsidiaries, and distributors.
Read more on NKE →
